Drugs / R348
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01733992 Comparator | Nov 2012 → Feb 2013 | dry eye syndrome | Rigel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02040623 Comparator | Mar 2014 → Jul 2016 | chronic graft versus host disease | Rigel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01900249 Comparator | Jul 2013 → Jul 2014 | keratoconjunctivitis | Rigel Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-08-13 | Rigel Pharmaceuticals | R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study rigel.com ↗ |
| 2013-05-22 | Rigel Pharmaceuticals | Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye rigel.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02040623 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase JAK3 inhibitor” CHEMBL5314384 ↗1“Tyrosine-protein kinase SYK inhibitor” CHEMBL5314384 ↗ |
| Modality | Small molecule | — CHEMBL5314384 ↗ |
| Route | Other | “R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day” NCT02040623 ↗ |
| Target | JAK3 | “Tyrosine-protein kinase JAK3 inhibitor” CHEMBL5314384 ↗ |
| Target | SYK | “Tyrosine-protein kinase SYK inhibitor” CHEMBL5314384 ↗ |